HCW BiologicsHCWB -9.28%39 Receivables Turnover is 122.30 as of Mar. 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $43.78 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, HCW Biologics ranks better than 98.34% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. HCW Biologics's Revenue for the
three
months ended in Mar. 2026 was $6.54 Mil. HCW Biologics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.05 Mil.
Hence, HCW Biologics's Receivables Turnover for the
three
months ended in Mar. 2026 was 122.30.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
HCW Biologics Receivables Turnover Related Terms
HCW Biologics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs KAPA, IMNN, MTVA: Receivables Turnover Comparison
For the Biotechnology subindustry, HCW Biologics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Receivables Turnover of 122.30 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #14 out of 841 companies in the Biotechnology industry, placing it in the top 1.7%.
Is HCW Biologics' Receivables Turnover too high?
HCW Biologics' current Receivables Turnover is 122.30. The Biotechnology industry median Receivables Turnover is 5.27. HCW Biologics' value of 122.30 is 2220.7% above this industry median. Based on the distribution chart, HCW Biologics ranks #14 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Receivables Turnover compare to KAPA and IMNN?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #14 out of 841 companies for Receivables Turnover. This places HCW Biologics in the top 2% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. HCW Biologics' value of 122.30 is 2220.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Receivables Turnover of 122.30 is 2220.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Receivables Turnover is 122.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.78, compared to a current price of $4.30 — trading 90.2% below its estimated fair value. The current Receivables Turnover is 122.30 and 2220.7% above the Biotechnology industry median of 5.27. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Receivables Turnover is 122.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $4.30 is trading 90.2% below its estimated GF Value™ of $43.78.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Receivables Turnover: 122.30
GF Value™: $43.78 vs. price of $4.30 (90.2% below fair value)
Industry Position: 2220.7% above the Biotechnology median (#14 of 841)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
